Primex Pharmaceuticals appoints new Global Commerical Head

The Swiss pharmaceutical company has appointed Dan Spacie as Global Commercial Head to the Executive Management Team

Dan Spacie, new Global Commercial Head to the Executive Management Team

Swiss pharmaceutical company Primex Pharmaceuticals AG has appointed of Dan Spacie, as Global Commercial Head to the Executive Management Team led by CEO Alan Knox.

Dan Spacie has joined Primex Pharmaceuticals from Syneos Health, where he was President of Commercial in Europe. Syneos Health is a fully integrated biopharmaceutical solutions organisation, CRO and Contract Commercial Organisation (CCO).

Prior to Syneos, Spacie held several leadership roles including Managing Director at STADA UK affiliates for five years. He has extensive international leadership experience in growing sales and enhancing the profitability of generics, branded pharmaceuticals and launching biopharmaceuticals.

"I look forward to working with our distribution partners in anticipation of making OZALIN available to children who face surgical intervention and emergency treatment. It is particularly gratifying to join Primex at a time when we are launching in the EU and beginning to expand to our global partner network," says Dan Spacie.

At Primex, Spacie is responsible for global Commercialisation working with both our partners and direct field forces across the portfolio and with the launch of OZALIN in EU. He will be part of the Executive Team headed by CEO Alan Knox and is based in Zug, Switzerland.

Knox said: "I am pleased that Primex can attract top talent such as Dan. We are a fast-growth company and he joins us during a significant period of transformation. Dan will help us to accelerate our launches in Europe, internationally and in the US."

Companies